Evidence mapPaperPMID 18358749Full record

ArticleJournal of diabetes and its complications

The relationship between glycemic control and platelet activity in type 2 diabetes mellitus.

Refik Demirtunc, Dursun Duman, Melih Basar, Mustafa Bilgi, Mehmet Teomete, Tayfun Garip

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Journal of diabetes and its complications. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06286878. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06286878 phase2 / phase3recruiting

Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes

Ran2021Enrolled80Registered outcomes4Posted comparisons0ConditionsAcute Coronary Syndrome, Diabetes, Myocardial Infarction, Ventricular DysfunctionArmsdapagliflozin, Placebo
Open the trial in the graph
NCT02377388 phase3completednot on this map

DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function

TypeinterventionalSponsorUniversity of Sao Paulo General HospitalRan2017 to 2020Enrolled74ConditionsPlatelet Aggregation During Acute Myocardial InfarctionArmssitagliptin OR saxagliptin, placebo
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 208 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Associations Between Mean Platelet Volume and Various Factors in Type 2 Diabetes Patients: A Single-Center Study from Poland.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Article
  16. Mean platelet volume for differentiating non-alcoholic fatty liver disease from non-alcoholic steatohepatitis: Is it ready for prime time?Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Refik DemirtuncDepartment of Internal Medicine, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
Dursun Duman
Melih Basar
Mustafa Bilgi
Mehmet Teomete
Tayfun Garip
Haydarpaşa Numune Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsPlatelet activity and aggregation potential, which are essential components of thrombogenesis and atherosclerosis, can be conveniently estimated by measuring mean platelet volume (MPV) as part of whole blood count. It has been shown that MPV was significantly higher in diabetes mellitus (DM); however, the effect of glycemic control on MPV has not been studied. The aim of this study was to investigate the relationship among MPV, glycemic control, and micro- and macrovascular complications in type 2 DM.

methodsSeventy patients with type 2 DM and 40 age- and sex-matched healthy individuals were enrolled. Diabetic patients were grouped into those with glycated hemoglobin (HbA1c) levels <or=7% (Group A, n=35 patients) and those with HbA1c >7% (Group B, n=35 patients). Initially, both groups were compared with regard to MPV, HbA1c, serum lipid levels, coronary artery disease, retinopathy, neuropathy, and nephropathy. Thereafter, Group B was called to monthly visits to obtain improved control glycemic control, which was defined as achievement of HbA1c <or=7%. At the end of 3 months of follow-up, Group B was reevaluated.

resultsMPV was significantly higher in patients with DM than in controls (8.7+/-0.8 fl vs. 8.2+/-0.7 fl, P=.002). In diabetic patients, there was a significant positive correlation between MPV and HbA1c levels (r=.39, P=.001) but not diabetic vascular complications. When we compared the two diabetic groups, Group B patients had significantly higher MPV than Group A (9.0+/-0.7 fl vs. 8.4+/-0.8 fl, P=.01). Thirty patients (86%) of Group B achieved improved glycemic control at the end of the 3 months. MPV of the patients with improved glycemic control were significantly decreased compared to baseline MPV (8.4+/-0.8 fl vs. 9.0+/-0.7 fl, P=.003).

conclusionsOur results suggested a close relationship between poor glycemic control and increased platelet activity in patients with type 2 DM. Furthermore, platelet activity recovered through improved glycemic control, which may prevent the possible role of platelets in cardiovascular events in these patients.

Indexed as

AdultAgedBlood GlucoseBlood PlateletsBlood PressureCoronary DiseaseDiabetes Mellitus, Type 2Diabetic AngiopathiesDiabetic NeuropathiesDiabetic RetinopathyFemaleGlycated HemoglobinHumansLipidsMaleMiddle AgedBlood GlucoseGlycated HemoglobinLipids

Identifiers

PMID18358749
OpenAlexW2169714812

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.